Article

Respiratory effects of nusinersen treatment in pediatric patients with spinal muscular atrophy types 2 and 3

2025-07-14

Abstract excerpt

<title>Abstract</title> <p> <bold>Introduction</bold> : Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder characterized by respiratory decline. While nusinersen improves motor function, its long-term respiratory effects in milder SMA types (2 and 3) remain unclear. This study evaluates pulmonary outcomes following 3 years of treatment. <bold>Methods</bold> : We retrospectively reviewed gen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 49f27617-d82c-53bb-a46e-03d5e96ef193
DOI: 10.21203/rs.3.rs-7029230/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Respiratory effects of nusinersen treatment in pediatric patients with spinal muscular atrophy types 2 and 3DOI 10.21203/rs.3.rs-7029230/v1Read

The Effects of Nusinersen Treatment on Respiratuar Status of Children with Spinal Muscular AtrophySemantic proximity Read

The respiratory impact of novel therapies for spinal muscular atrophy.Semantic proximity Read

Respiratory management of spinal muscular atrophy type 2.Semantic proximity Read

Natural History of Respiratory Muscle Strength in Spinal Muscular Atrophy: A Prospective National Cohort StudySemantic proximity Read

Treatment of 5q-spinal muscular atrophy with nusinersen in Southern China: A single center retrospective studySemantic proximity Read

Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysisSemantic proximity Read

SPINAL MUSCULAR ATROPHY: CLINICAL CHARACTERIZATION AND EVOLUTION AFTER TREATMENT WITH NEW MODIFYING THERAPIESSemantic proximity Read

Effect of nusinersen after 3 years of treatment in 57 young children with SMA in terms of SMN2 copy number or type.Semantic proximity Read

Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.Semantic proximity Read

Effect of nusinersen after three years of treatment in 61 young children with SMA type 1 or 2: a French real-life observational studySemantic proximity Read

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE studySemantic proximity Read

Deficiencies in the medical care of SMA: evidence from a nationwide patient registry in GermanySemantic proximity Read